Last reviewed · How we verify
Cetuximab - Cohort Expansion
Cetuximab - Cohort Expansion is a Biologic drug developed by Wugen, Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | Cetuximab - Cohort Expansion |
|---|---|
| Sponsor | Wugen, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (PHASE1)
- BBO-11818 in Adult Subjects With KRAS Mutant Cancer (PHASE1)
- A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation (PHASE1)
- A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification (PHASE1)
- A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation (PHASE1)
- JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation (PHASE1, PHASE2)
- A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation (PHASE1)
- A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cetuximab - Cohort Expansion CI brief — competitive landscape report
- Cetuximab - Cohort Expansion updates RSS · CI watch RSS
- Wugen, Inc. portfolio CI
Frequently asked questions about Cetuximab - Cohort Expansion
What is Cetuximab - Cohort Expansion?
Cetuximab - Cohort Expansion is a Biologic drug developed by Wugen, Inc..
Who makes Cetuximab - Cohort Expansion?
Cetuximab - Cohort Expansion is developed by Wugen, Inc. (see full Wugen, Inc. pipeline at /company/wugen-inc).
What development phase is Cetuximab - Cohort Expansion in?
Cetuximab - Cohort Expansion is in Phase 1.
Related
- Manufacturer: Wugen, Inc. — full pipeline
- Compare: Cetuximab - Cohort Expansion vs similar drugs
- Pricing: Cetuximab - Cohort Expansion cost, discount & access